ATB1651 / AmtixBio - LARVOL DELTA

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: AmtixBio Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Jul 2024

Enrollment open • Trial initiation date • Infectious Disease

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: AmtixBio Co., Ltd.

New P2 trial • Infectious Disease

Toxicity of a novel antifungal agent (ATB1651 gel) in Yucatan minipigs (Sus scrofa) following 4 weeks of daily dermal administration. (PubMed, Toxicol Res) - "The no-observed-adverse-effect level of ATB1651 gel was 3.0% with regard to topical and systemic toxicity in both male and female minipigs. Collectively, our results imply that ATB1651 gel is a safe candidate for clinical development as an antifungal drug with a wide therapeutic window."

Journal • Dermatology

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: AmtixBio Co., Ltd. | Recruiting ➔ Completed | N=60 ➔ 30 | Trial completion date: Feb 2024 ➔ Sep 2023 | Trial primary completion date: Sep 2023 ➔ Jun 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: AmtixBio Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2023 ➔ Feb 2024 | Trial primary completion date: Apr 2023 ➔ Sep 2023

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease